Viva BioInnovator
VC Fund
Shanghai, China
Viva BioInnovator is a VC fund in Shanghai focused on Biotechnology and Health Care. Viva BioInnovator (VBI) is the specialized investment and incubation arm of Viva Biotech Holdings. We focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup's growth from idea to clinical program. VBI'sunique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1" transformation. This spark launched our "equity for service (EFS)" investment and incubation model. VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy. If you would like to learn more about us, please visit: www.vivabioinnovator.com Or send an email to innovation@vivabiotech.com If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com
- Total investments:
- 65
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries Viva BioInnovator invests in
Stages Viva BioInnovator invests in
Countries Viva BioInnovator invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$20M
- Series A
- $3M–$20M
- Venture - Series Unknown
- $3.2M–$8.6M
Investment Focus
Industry
- Biotechnology 48 (74%)
- Health Care 29 (45%)
- Medical 22 (34%)
- Therapeutics 21 (32%)
- Pharmaceutical 14 (22%)
Stage
- Venture - Series Unknown 20 (31%)
- Seed 18 (28%)
- Series A 16 (25%)
- Series B 8 (12%)
- Series C 1 (2%)
Country
- United States 41 (63%)
- China 5 (8%)
- Canada 4 (6%)
- Japan 1 (2%)
- France 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cheney Mao
Founder, Chairman, CEO
|
Founder, Chairman, CEO | Total investments: 0 | Find email | |
|
Han Dai
CBO and Head of Investment
|
CBO and Head of Investment | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $23.5M / Series B / Feb 09, 2026 | ||
| Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $5M / Series A / Apr 01, 2025 | ||
|
Proviva Therapeutics, Inc
|
Prodrug design platform for cytokines and other fusion proteins | $18M / Series A / Mar 05, 2024 | |
| TechnoDerma Medicines focuses on the research and development of innovative skin drugs for external use. | Series A / Jan 15, 2024 | ||
Calira Therapeutics
|
Calira Therapeutics is a biotech company focusing on allosteric inhibitors of CaMK2 for the treatment of diabetes and heart failure. | Venture - Series Unknown / Jan 01, 2024 | |
| Exarta Therapeutics is a pre-clinical biological startup company. | Venture - Series Unknown / Jan 01, 2024 | ||
| Full Circles Therapeutics is a biotechnology company that develops genome surgery platforms to treat genetic diseases and cancer. | Venture - Series Unknown / Jan 01, 2024 | ||
| Early stage biotechnology start-up developing next generation cytokine therapeutics | $20M / Series B / Sep 28, 2023 | ||
| WM Therapeutics is a drug discovery company that discovers and develops novel cancer therapies that limit tumor-autonomous growth and stimulate the immune system to attack the tumor. | Venture - Series Unknown / Jan 01, 2023 | ||
| NAKI Therapeutics is a research-focused biopharmaceutical company developing Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy used to kill cancer cells effectively and safely compared to existing treatments. The company was founded in 2020 and is headquartered in Summit, New Jersey. | Venture - Series Unknown / Jan 01, 2023 | ||
| See all 65 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Viva BioInnovator invest in?
Viva BioInnovator invests primarily in Biotechnology, Health Care and Medical startups, most often at Venture - Series Unknown and Seed stage. Most of the 65 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Viva BioInnovator invest in?
Viva BioInnovator typically joins rounds of $1M–$20M at Seed, $3M–$20M at Series A and $3.2M–$8.6M at Venture - Series Unknown. These are whole funding-round sizes, not Viva BioInnovator's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Viva BioInnovator took part in.
How do I contact Viva BioInnovator?
Public channels for Viva BioInnovator include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Viva BioInnovator?
The team at Viva BioInnovator includes Cheney Mao (Founder, Chairman, CEO) and Han Dai (CBO and Head of Investment). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
